Engene Holdings Inc. shares rise 4.11% after-hours after achieving target enrollment milestone for pivotal cohort of LEGEND trial.

Engene Holdings Inc. rose 4.11% in after-hours trading, driven by the company's announcement that it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid in patients with high-risk, non-muscle invasive bladder cancer. The company expects to overenroll in its pivotal cohort, which is a positive development for the stock.